EMBO Workshop on Tuberculosis 2022
From innovation to intervention
September 12-16, 2022
CIS auditorium, Institut Pasteur
Monday, September 12, 2022
2.00 pm-5.30 pm
Welcome addresses & Opening Keynote lecture
5.45 pm-7.00 pm
Chair: Roland Brosch, Institut Pasteur, France
5.45 pm

Welcome addresses, the Director of the Institut Pasteur Stewart COLE and members of the organizing committee

Stewart Cole
Institut Pasteur, Paris, France
6.15 pm

Developing a controlled human infection model for TB

Helen McShane
University of Oxford, Oxford, United Kingdom
Welcome Reception (buffet dinner) at CIS Institut Pasteur
7.00 pm-9.00 pm
Tuesday, September 13, 2022
Session1: From Mycobacterial genomics to global epidemiology & resistance prediction
08.30 am-10.15 am
Chairs: Howard Takiff, Institut Pasteur, France - Philip Supply, CIIL - Center for Infection and Immunity of Lille, France
08.30 am

Transmission and evolution of MDR Mycobacterium tuberculosis complex strains

Stefan Niemann
Molecular and Experimental Mycobacteriology, Research Center Borstel, Germany German Center for Infection Research, Borstel Site, Germany
08.55 am

Cis-regulatory effects of constitutive and context-specific intercellular mosaic methylation in M. tuberculosis

Samuel Modlin
San Diego State University, San Diego, United States
09.10 am

Mycobacterial diversity’s lens on public health

Bouke De Jong
Institute of Tropical Medicine, Antwerp, Belgium
09.35 am

Epistasis defines the transmission fitness of multidrug-resistant Mycobacterium tuberculosis

Etthel Windels
Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland Swiss Institute of Bioinformatics, Lausanne, Switzerland
09.50 am

Fast RNA-based drug susceptibility testing fills the gap between slow phenotypic and ultra-fast DNA-based resistance detection

Margo Maex
Scientific Service Bacterial Diseases - Infectious Diseases in Humans, Siensano, Brussels, Belgium
Coffee break
10.15 am-10.45 am
Session 2: Mycobacterial Biology & Physiology I
10.45 am-12.30 pm
Chairs: Sabine Ehrt, Weill Cornell Medical College, United States - Jeremy Rock, Rockefeller University, United States
10.45 am

Finding the most "essential" essential genes in M. tuberculosis

Jeremy Rock
Rockefeller University, New York, United States
11.10 am

ADP-ribosylation of DNA in Mycobacterium tuberculosis – from “How” to “Why?”

Graham Stewart
Dept of Microbial Sciences, University of Surrey, Guildford, United Kingdom
11.25 am

TbD1 deletion in Mycobacterium tuberculosis adaptation to the human host

Daria Bottai
University of Pisa, Pisa, Italy
11.50 am

Phase variation as a major mechanism of adaptation in Mycobacterium tuberculosis complex

Maha Farhat
Biomedical Informatics, Harvard Medical School, Boston, United States
12.05 pm

Mycobacterial determinants of intrinsic multidrug tolerance and resistance

Sabine Ehrt
Cornell Medical College, New York, United States
12.30 pm-1.45 pm
Poster session 1
1.45 pm-3.30 pm
Session 3: Mycobacterial Biology & Physiology II
3.30 pm-4.55 pm
Chairs: Giulia Manina, Institut Pasteur, France - Sarah Fortune, Harvard University, United States
3.30 pm

It’s about time:  Antibiotic resilience as a driver of treatment failure in tuberculosis

Sarah Fortune
Harvard University, Boston, United States
3.55 pm

Exploring horizontal gene transfer in predominantly clonal tuberculosis-causing mycobacteria

Jan Madacki
Unit for Integrated Mycobacterial Pathogenomics, Institut Pasteur, Paris, France
4.10 pm

The Mycobacterium tuberculosis protein O-phosphorylation landscape

Christoph Grundner
Seattle Children's Research Institute, Seattle, United States University of Washington, Seattle, United States
4.25 pm

Pheno-tuning: A strategy to undermine mycobacterial cells

Giulia Manina
Laboratory of Microbial Individuality and Infection, Institut Pasteur, Paris, France
Coffee break
4.50 pm-5.20 pm
Session 4: Drug development & resistance/persistence management
5.20 pm-6.50 pm
Chairs: Bree Aldridge, Tufts University, United States - Santiago Ramón García, ARAID Foundation, Spain
5.20 pm

OPTIKA, a new high content in vitro kill-kinetic assay to evaluate the efficacy of novel anti-TB drug combinations

Santiago Ramón García
ARAID Foundation, Zaragoza, Spain
5.45 pm

Targeted protein self-degradation as a novel therapeutic strategy for tuberculosis

Harim Won
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, United States
6.00 pm

Sanfetrinem Cilexetil - From (re-) discovery to clinical trial

Robert Bates
GSK Medicines Development Centre, Tres Cantos, Spain
6.25 pm

Design Principles of Combination Therapies for TB 

Bree Aldridge
Tufts University, Boston, United States
Wine cheese reception at CIS Institut Pasteur
7.00 pm-9.00 pm
Wednesday, September 14, 2022
Session 5: Biomarkers and host responses
08.30 am-10.15 am
Chairs: Lalita Ramakrishnan, University of Cambridge, United Kingdom - Simone Joosten, Leiden University, The Netherlands
08.30 am

Mycobacterial growth control in natural vs vaccine induced protection

Simone Joosten
Department of Infectious Diseases, Leiden University, Leiden, The Netherlands
08.55 am

A Mycobacterium tuberculosis fingerprint in human breath allows tuberculosis diagnosis

Jérôme Nigou
Institut de Pharmacologie et de Biologie Structurale, CNRS - University of Toulouse, France
09.10 am

Mycobacterial virulence and macrophage mitochondrial metabolism face off

Lalita Ramakrishnan
University of Cambridge, Cambridge, United Kingdom
09.35 am

Human Antibodies Targeting a Transporter Mediate Protection Against Tuberculosis

Natalia Freund
Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
09.50 am

Roles of antibody characteristics in the protection against TB - from epitope to Fc and isotype significance

Jacqueline Achkar
Albert Einstein College, New York, United States
Coffee break
10.25 am-10.55 am
Session 6: Live attenuated vaccines & mechanisms of attenuation
10.55 am-12.25 pm
Chairs: Carlos Martin, University of Zargossa, Spain - Andreas Kupz, James Cook University, Australia
10.55 am

BCG::ESAT6-PE25SS – a new recombinant BCG strain – insights into delivery and protective mechanisms

Andreas Kupz
James Cook University, Cairns, Australia
11.20 am

MTBVAC from the lab to clinical efficacy trials, the moment of truth 100 years after BCG

Carlos Martin
University of Zargossa, Zaragossa, Spain
11.45 am

Mind the Gap: Functional Characterisation of the Mycobacterial Virulence Protein Erp

Jonathan Shanahan
Department of Medicine, Molecular Immunity Unit, University of Cambridge, United Kingdom
12.00 pm

ESX-1-proficient BCG vaccines: challenges and opportunities

Roland Brosch
Institut Pasteur, Paris, France
12.25 pm-1.45 pm
Poster session 2
1.45 pm-3.15 pm
Session 7: Mycobacterial Host-Pathogen interactions
3.15 pm-5.00 pm
Chairs: Maximiliano G. Gutierrez, The Francis Crick Institute, United Kingdom - Olivier Neyrolles, Institut for Pharmacology and Structural Biology, France
3.15 pm

Mycobacterial resistance to metal stress during infection

Olivier Neyrolles
Institut for Pharmacology and Structural Biology, Toulouse, France
3.40 pm

Pre-existing heterogeneity of inducible nitric oxide synthase expression drives differential growth of Mycobacterium tuberculosis in macrophages

Ophélie Rutschmann
UPKIN, EPFL, Lausanne, Switzerland
3.55 pm

Is Mycobacterium tuberculosis the greatest cell biologist in the world?

Maximiliano G. Gutierrez
The Francis Crick Institute, London, United Kingdom
4.20 pm

Making mistakes in the goldilocks zone: mistranslation as a novel form of mycobacterial virulence

Babak Javid
UCSF, San Francisco, United States Tsinghua University, Beijing, China
4.35 pm

Drivers of diversity in tuberculosis in vivo

David Russell
Cornell University, Ithaca, United States
Coffee break
5.00 pm-5.30 pm
Session 8: Non-rodent animal models for TB
5.30 pm-7.00 pm
Chairs: Laura Via, NIH NIAID, United States - Stephen Gordon, University College Dublin, Ireland
5.30 pm

One Health analysis of Mycobacterium bovis

Stephen Gordon
University College Dublin, Dublin, Ireland
5.55 pm

Drosophila melanogaster as a host model to study mycobacterial host-pathogen interactions

Marte Singsås Dragset
Centre of Molecular Inflammation Research (CEMIR), Norwegian University of Science and Technology, Trondheim, Norway Germans Trias i Pujol Research Institute, Badalona, Spain
6.10 pm

Implementation of a cynomolgus macaque model of tuberculosis

Candie Joly
IMVA-HB/IDMIT, CEA, Fontenay Aux Roses, France
6.35 pm

Efficacy of TB regimens in an NHP model: focusing on pathology

Laura Via
Tuberculosis Research Section, NIH NIAID, Bethesda, United States
On your own for dinner
7.00 pm-11.00 pm
Thursday, September 15, 2022
Session 9: Emerging mycobacterial pathogens
08.30 am-10.15 am
Chairs: Marcel Behr, McGill University, Canada - Jean-Louis Herrmann, Université Paris-Saclay, France
08.30 am

Mycobacterium abscessus fitness modulation in vivo: a bacterial trait or ... a bacterial trait

Jean-Louis Herrmann
Université Paris-Saclay, Saint-Quentin-en-Yvelines, France
08.55 am

The small RNA B11 is a master regulator of ESX-4 secretion and M. abscessus pathogenesis

Daniel Barkan
Hebrew University, Rehovot, Israel
09.10 am

A drug candidate against Mycobacterium abscessus and other cystic fibrosis pathogens

Giulia Degiacomi
Department of Biology and Biotechnologies, University of Pavia, Italy
09.25 am

Unpacking the molecular determinants of Mycobacterium abscessus infections

Virginia Pichler
Microbiology & Immunology, University of British Columbia, Vancouver, Canada CNRS. UMR 9004, Université de Montpellier, Institut de Recherche en Infectiologie de Montpellier (IRIM), France
09.40 am

M. orygis: zTB’s missing link

Marcel Behr
McGill University, Montreal, Canada
Coffee break
10.05 am-10.35 am
Session 10: Host-responses and host-directed therapies
10.35 am-12.35 pm
Chairs: Priscille Brodin, INSERM, Institut Pasteur de Lille, France - Jan Rybniker, University of Cologne, Germany
10.35 am

Exploiting MAP-kinase signaling as a host directed target in tuberculosis

Jan Rybniker
University of Cologne, Cologne, Germany
11.00 am

WNT6/ACC2-induced storage of triacylglycerols in macrophages is exploited by Mycobacterium tuberculosis

Julius Brandenburg
Research Center Borstel, Germany
11.15 am

Targeting human macrophages to improve the efficacy of anti-TB drugs

Ludovic Tailleux
Institut Pasteur, Paris, France
11.40 am

Host regulators of phagosomal membrane integrity in TB infection

Charul Jani
Dr. Amy Barczak, Ragon Institute of MGH, MIT and Harvard, Cambridge, United States
11.55 am

Neutrophil-driven immunosuppressive feedback loops underlying susceptibility to M. tuberculosis

Dmitri Kotov
Divison of Immunology and Pathogenesis, University of California, Berkeley, United States Howard Hughes Medical Institute, University of California, Berkeley, United States
12.10 pm

Is intracellular activity a potent driver for novel TB drug development?

Priscille Brodin
INSERM, Institut Pasteur de Lille, France
12.35 pm-1.45 pm
Poster session 3
1.45 pm-3.15 pm
Session 11: Biochemistry & chemical biology / drugs I
3.15 pm-4.35 pm
Chairs: Hedia Marrakchi, IPBS, France - Clifton Barry, NIH NIAID, United States
3.15 pm

Exploiting a Bacterial Enzyme for Selective Prodrug Activation: Mycobacterium tuberculosis N-acetylates 5-aminomethyl oxazolidinones

Clifton Barry
Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institutes of Health, Bethesda, United States
3.40 pm

Expression of a novel mycobacterial phosphodiesterase successfully lowers cAMP levels resulting in reduced tolerance to cell-wall targeting antimicrobials

Gerald Larrouy-Maumus
MRC-CMBI Imperial College London, United Kingdom
3.55 pm

Targeting mycolic condensation enzymes: from screens to insights

Hedia Marrakchi
IPBS, Toulouse, France
4.20 pm

Solution structure of the type I polyketide synthase Pks13 from Mycobacterium tuberculosis

Cécile Bon
IPBS, CNRS/Université de Toulouse, France
Coffee break
4.35 pm-5.00 pm
Session 12: Biochemistry & chemical biology / drugs II
5.00 pm-6.05 pm
Chairs: Thomas Marlovits, Institute of Structural and Systems Biology, Germany - Pedro Alzari, Structural Microbiology, Institut Pasteur, France
5.00 pm

Novel insights into mycobacterial cell division mechanisms using C. glutamicum as a model organism

Annemarie Wehenkel
Institut Pasteur, Paris, France
5.25 pm

Compartment-specific proximity labeling uncovers the exposure of Type VII ESX secretion system substrates to the mycobacterial periplasm

Jessica Seeliger
Department of Pharmacological Sciences, Stony Brook University, United States
5.40 pm

Structure and dynamics of a mycobacterial type VII secretion system

Thomas Marlovits
Institute of Structural and Systems Biology, Hamburg, Germany
Congress dinner (Musée des Arts Forains) (with reservation)
8.00 pm-11.00 pm
Friday, September 16, 2022
Session 13: Human susceptibility & Clinical trials
09.00 am-10.30 am
Chairs: Anne O'Garra, The Francis Crick Institute, United Kingdom - Gerhard Walzl, Stellenbosch University, South Africa
09.00 am

Human Genetics of tuberculosis : the TYK2 story

Laurent Abel
Inserm, Necker, Paris, France
09.25 am

Systems immunomonitoring to support development of new treatments and vaccines for TB

Darragh Duffy
Institut Pasteur, Paris, France
09.40 am

Transcriptional signatures reveal the immune response underlying progression and pathogenesis in tuberculosis

Anne O'Garra
The Francis Crick Institute, London, United Kingdom
10.05 am

Using Biomarkers to Predict TB Treatment Duration

Gerhard Walzl
Stellenbosch University, Stellenbosch, South Africa
Coffee break
10.30 am-11.00 am
Session 14: Closing Keynote lecture and outlook
11.00 am-12.00 pm
Chairs: Roland Brosch, Institut Pasteur, France - Pedro Alzari, Structural Microbiology, Institut Pasteur, France
11.00 am

Drugs hug, bugs chug - genetic-chemical synergy in mycobacteria

Eric Rubin
Harvard University, Boston, United States
11.50 am

Closing comments / End of congress


plateforme dédiée aux manifestations
Tel. : 01 84 17 20 55 / 06 89 19 34 06
E-mail :
La première plateforme Française de gestion de manifestations regroupant la billeterie, la gestion des hébergements, une boutique en ligne, la gestion des surfaces d'exposition et la gestion complète du programme scientifique.
Organisation de Congrès, manifestations, Séminiaires, Colloques